Friday, 25 May 2012

Neptune Stock Moving Strongly On Heels Of Solid F2012 Results


Neptune Technologies & Bioressources
TSX: NTB - NASDAQ: NEPT
Basic Shares: 48.2 million
Fully diluted: 53.9 million
**********************************

As of this writing, the stock hit a morning high of $4.01 (CDN) before settling into the $3.80 range on more than a million shares traded, combining U.S. and Canadian activity. Several days ago, Neptune was trading just above $3.00.

Notably, F2012 (Feb. 29) saw record revenues on the platform side of Neptune’s business model being nutraceutical sales.  Consolidated results reflect Neptune’s obligations via its 57% ownership of Acasti Pharma and 100% ownership of private NeuroBioPharm.

2012 financial highlights include:

Nutraceutical Business Results
  • Nutraceutical revenues increased by 15% to a record $19,113,000 for the fiscal year ended February 29, 2012, up from $16,583,000 achieved during the corresponding period ended February 28, 2011.
  • Net income from nutraceutical business improved by 136% and reached a net income of $2,384,000 for the fiscal year ended February 29, 2012, compared to a net income of $1,010,000 for the corresponding period ended February 28, 2011.
  • EBITDA from nutraceutical business for the fiscal year ended February 29, 2012 reached $2,690,000, compared to$2,818,000 obtained during the corresponding period ended February 28, 2011.
Consolidated Results
  • Revenues increased by 15% to $19,124,000 for the fiscal year ended February 29, 2012, up from $16,583,000 achieved during the corresponding period ended February 28, 2011.
  • Earnings for the year ended February 29, 2012 resulted into a net loss of ($4,593,000) compared to a net loss of ($1,693,000), for the corresponding period ended February 28, 2011.
  • Consolidated EBITDA for the fiscal year ended February 29, 2012 was ($2,593,000), compared to $258,000 obtained during the corresponding period ended February 28, 2011
Neptune management will be hosting a conference call to update investors on a number of corporate developments over and above the financial discussion on May 31 at 4:30pm (ET). Some of the people who will be on the call are currently out of country.
  • Year End financial results
  • Commercial progress
  • Plant expansion
  • Intellectual property  
  • NeuroBioPharm
  • Acasti Pharma Update

Details on the conference call will be released on the week of May 28, 2012.

To view the full news release, please click here.